Xeris Biopharma (NASDAQ: XERS) awards director 24,193 RSUs and 32,996 options
Rhea-AI Filing Summary
Xeris Biopharma director Dawn Halkuff reported a mix of equity grants and a pre-planned share sale. She received 24,193 shares of common stock as a restricted stock unit grant and 32,996 stock options at $6.15 per share, both vesting in full on the earlier of June 4, 2026 or the company’s next annual stockholder meeting, subject to continued service. On the same date, she sold 20,000 shares of common stock at a weighted average price of $6.0943 per share under a Rule 10b5-1 trading plan adopted on September 4, 2025, and held 95,000 shares directly afterward. She also had 5,410 shares held indirectly through the Dawn Halkuff Revocable Trust, for which she disclaims beneficial ownership except to the extent of her pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Buyer: 4,193 shares
Net Buy
4 txns
Insider
HALKUFF DAWN
Role
Director
Sold
20,000 shs ($122K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 32,996 | $6.15 | $203K |
| Sale | Common Stock | 20,000 | $6.0943 | $122K |
| Grant/Award | Common Stock | 24,193 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 32,996 shares (Direct);
Common Stock — 119,193 shares (Direct);
Common Stock — 5,410 shares (Indirect, By; DAWN HALKUFF REVOCABLE TRUST U/A DTD 08/25/2017)
Footnotes (5)
- F1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025.
- F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.960 to $6.170, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
- F4. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- F5. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
Key Figures
RSU grant: 24,193 shares
Stock options granted: 32,996 options at $6.15
Shares sold: 20,000 shares at $6.0943
+3 more
6 metrics
RSU grant
24,193 shares
Restricted stock unit grant on June 4, 2026
Stock options granted
32,996 options at $6.15
Option grant under 2018 Plan, expiring June 4, 2036
Shares sold
20,000 shares at $6.0943
Open-market sale on June 4, 2026
Direct holdings after
95,000 shares
Common stock directly owned following transactions
Indirect holdings
5,410 shares
Held via Dawn Halkuff Revocable Trust
10b5-1 plan adoption
September 4, 2025
Date trading plan for sale was adopted
Key Terms
Rule 10b5-1 trading plan, restricted stock unit, 2018 Stock Option and Incentive Plan, pecuniary interest, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transaction was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock unit financial
"These shares were acquired pursuant to a restricted stock unit grant"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
2018 Stock Option and Incentive Plan financial
"acquired pursuant to a grant under the Company’s 2018 Stock Option and Incentive Plan"
pecuniary interest financial
"disclaims beneficial ownership of these securities except to the extent of his pecuniary interest"
stock options financial
"These stock options were acquired pursuant to a grant under the Plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Xeris Biopharma (XERS) director Dawn Halkuff report in this Form 4?
Dawn Halkuff reported a grant of common shares and stock options plus an open-market sale. She received 24,193 restricted stock units, 32,996 stock options, and sold 20,000 common shares, all dated June 4, 2026.
What equity awards did Dawn Halkuff receive from Xeris Biopharma (XERS)?
She received 24,193 shares through a restricted stock unit grant and 32,996 stock options. Both awards were granted under Xeris Biopharma’s 2018 Stock Option and Incentive Plan on June 4, 2026, with full vesting tied to service through the next annual meeting.
When do Dawn Halkuff’s new Xeris Biopharma (XERS) RSUs and options vest?
The restricted stock units and stock options vest in full on the earlier of June 4, 2026 or the date of Xeris Biopharma’s next annual meeting of stockholders, provided she continues in service through that vesting date.